Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 875.90M P/E - EPS this Y 23.70% Ern Qtrly Grth -
Income -15.37M Forward P/E -11.66 EPS next Y 54.80% 50D Avg Chg -9.00%
Sales - PEG -0.21 EPS past 5Y 58.11% 200D Avg Chg -25.00%
Dividend N/A Price/Book 4.29 EPS next 5Y 83.80% 52W High Chg -59.00%
Recommedations 3.00 Quick Ratio 3.93 Shares Outstanding 47.98M 52W Low Chg 25.00%
Insider Own 11.86% ROA -37.43% Shares Float 42.38M Beta -0.62
Inst Own 29.11% ROE -8.35% Shares Shorted/Prior 15.91M/17.68M Price 20.98
Gross Margin - Profit Margin - Avg. Volume 840,450 Target Price 103.00
Oper. Margin - Earnings Date Nov 5 Volume 525,756 Change -3.94%
About Cassava Sciences, Inc.

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Cassava Sciences, Inc. News
11/18/24 Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer
11/15/24 Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year?
11/12/24 What Makes Cassava Sciences (SAVA) a New Buy Stock
11/07/24 Cassava Sciences Reports Q3 2024 Financial and Operating Results
10/31/24 Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024
10/30/24 Institutions along with individual investors who hold considerable shares inCassava Sciences, Inc. (NASDAQ:SAVA) come under pressure; lose 6.7% of holdings value
10/28/24 MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain
10/17/24 Cassava Sciences, Inc. (SAVA): Jim Cramer Says Eli Lilly Has The Edge
10/09/24 Cassava Sciences Advances Alzheimer’s Trials Amid SEC Settlement
10/09/24 Cassava Sciences: Phase III trials storm ahead amid controversy
10/08/24 Sector Update: Health Care Stocks Rise Late Afternoon
10/08/24 What's Going On With Alzheimer's-Focused Cassava Sciences On Tuesday?
10/04/24 An Alzheimer’s drugmaker is accused of data ‘manipulation.’ Should its trials be stopped?
09/30/24 SAVA Stock Down on Settling Misleading Alzheimer's Study Data Claims
09/30/24 Company News for Sep 30, 2024
09/27/24 Why Cassava Sciences Stock Dived by Almost 11% Today
09/27/24 These Stocks Moved the Most Today: Bristol Myers, Costco, EchoStar, Cassava, DJT, Wynn, HP Inc., Acadia Healthcare, and More
09/27/24 Cassava Sciences agrees to $40M SEC fine over Alzehimer's claims
09/27/24 Top Midday Decliners
09/27/24 Cassava's Stock Drops After It Agrees to Pay $40M to Settle SEC Alzheimer's Claims
SAVA Chatroom

User Image NastyyTrades Posted - 9 minutes from now

$SAVA When is finals results on P3 coming out? All I can find is before year-end

User Image Hooper04 Posted - 58 seconds ago

$SAVA this is going to land, and I'm loading the boat!!

User Image Hooper04 Posted - 4 minutes ago

$SAVA

User Image secretowl Posted - 25 minutes ago

$SAVA Note to the many first-time investors: This is a binary trade that will move sharply up or down depending on a trial outcome. You should absorb all information before opening a position. The number of obviously very young people trying to turn this into a "meme pump" and "blocking all the bears/bulls" is concerning. It's an FDA trial stock. It's not Gamestop. Social sentiment has no effect. This likely means very few have properly hedged their positions either...

User Image bolo44 Posted - 1 hour ago

$SAVA they can pump this to $100 at any moment!

User Image VetforVets Posted - 2 hours ago

$SAVA added to my wallpaper.

User Image History101 Posted - 3 hours ago

$SAVA from fibonacci1170: SAVA failed to publicly disclose that its analysis only included 37 out of 64 phase2b participants. The other 27 were excluded for very good reasons (ceiling effects). These 27 included participants who were: (1) crazy sick, (2) hardly sick, (3) no simufilam in blood despite being in the treatment arm, (4) patients who didn't follow the protocol of 2 pills/day, (5) patients who didn't understand/follow the test instructions. You will have to be a low-IQ dimwit researcher to include these participants in any analysis. Yes, SAVA made the above "mistakes", but these guys are hardcore researchers, and not PR specialists. Not disclosing in a PR all the reasons for excluding those 27 participants is hardly a crime. SEC fines were justified, but science-wise, the phase2b results are pristine. I am now nearly 100% confident phase-3 results will blow out the SEC+DOJ+bigpharma+shorts+liars

User Image AlphaDonMega Posted - 3 hours ago

$SAVA Hard to believe this BioScam is still dragging along..

User Image WallStreetBuyDip Posted - 3 hours ago

My only strategy since 2019 has been to buy when H% is low. Nothing else. Keep it simple and consistent. The results prove again and again why I‘ll only stick with this strategy Will trade $SAVA like how I did for others.

User Image McBlik Posted - 3 hours ago

$SAVA https://youtu.be/TEl6SbXR5hc?si=fq9bhbsd6lXn2njy

User Image Habagou Posted - 4 hours ago

$SAVA does anyone know if the owner of the Cassava discord got his PhD in paint mixing from Home Depot or Loews?

User Image StockCapture Posted - 4 hours ago

$SAVA WEN Phase 3 results?

User Image TwittStoxx Posted - 4 hours ago

$SAVA Why is Pharama-bra still being naughty ?? “Martin Shkreli, the former pharmaceutical executive, was ordered to pay $64.6 million in profits he and his company gained from inflating the price of the life-saving drug Daraprim. Additionally, he was barred from participating in the pharmaceutical industry for life.“ He, along with his minions who post on here, are a-holes for life.

User Image Twits_Ghost Posted - 4 hours ago

$SAVA 🐂

User Image TwittStoxx Posted - 4 hours ago

$SAVA Pharma Braaahhh Must Short SAVA to pay 64.6 million back for his evil deeds…

User Image Braveheart_13 Posted - 4 hours ago

$SAVA I almost feel bad for the lemmings and conspiracy theorists on this board - Wall Street is going to eat your lunch money

User Image mistermj Posted - 5 hours ago

$SAVA Fake news

User Image Major_Bagholder Posted - 5 hours ago

$SAVA https://x.com/chenkojira/status/1859658593588613336?s=46

User Image Rourou03 Posted - 5 hours ago

$SAVA

User Image arnolddiver Posted - 5 hours ago

$SAVA Biotechs are gonna rip monday because of Trump’s pick for FDA chief tonight. The dude, Dr. Marty Makary, is a Johns Hopkins surgeon who specializes in oncology and has the same views as RFK JR. Both want to fight big pharma corruption. IMO this guy will support small caps and will love the safety profile of Simufilam. We just need positive data next month and we will fly. Big pharma can’t push us down nor its paid cronies. Now I understand the pro MAGA comments by Matt Nachtrab. I’m sure he’s already advocating and has the right connections in the new adminstration.

User Image Dfw_Birdman Posted - 5 hours ago

$SAVA yall hear about the wife of @RoyMunson69 she sleeps with several of his neighbors. Krazeee

User Image NolAsrtormZ Posted - 5 hours ago

$SAVA pharma bro, feuerstein vrs retail

User Image kay91667 Posted - 5 hours ago

$SAVA This is very bad. "We learned from the SEC that Burns received the full data set, which showed the orange line. Burns presumably could not stand the idea of the drug demonstrating the exact opposite of what an Alzheimer’s drug could do. Not satisfied in manipulating the data only to show an equivocal outcome, Burns removed nearly half of the data to demonstrate that simufilam aided cognition. For those who do not follow scientific protocols or experiments, this is a cardinal sin. It is extremely unethical, which is why Burns is no longer with Cassava. In my view, this is worse behavior than Wang’s! Wang deals in a world of lab science—most of it doesn’t replicate. It is inexact, fraught with ‘translational’ risk. In this trial, Dr. Burns dealt in a world of humans. It is impossible for Burns to misunderstand just how evil it is to change this data before revealing it. I cannot understate enough how disgusting this is."

User Image Iwantmorestonks Posted - 6 hours ago

$SAVA bulls reported me yesterday and got me banned for 24 hours for warning people about SAVA. I guess karma was a b!each to them today

User Image TwittStoxx Posted - 6 hours ago

$SAVA Martin ‘loose arse’ Shreekel has 60k subs on YouTube….He’s got nothing better than trashing SAVA. He deserves to lose his rear end within the month.

User Image Twits_Ghost Posted - 7 hours ago

$SAVA Lotta cockroaches posting today. Holding all the way baby.

User Image Hooper04 Posted - 7 hours ago

$SAVA i know, maybe I'll hire people to bring in bad news at the end of phase 3?! Brilliant! Play the game wisely, and this is a warning to all, your one whale away from being fucked beyond your means. However, I own my shares, and this is going to be a retirements worth of action, and I'm here for it. Short it more, I fucking want you too you dumb assess!!! Lmfao!!

User Image Richfdd Posted - 7 hours ago

$SAVA

User Image FindingFacts Posted - 7 hours ago

$SAVA Anything related to the company's strategy to commercialize the drug will trigger a pop. There are many of them, such as numbers opt to continue the extension, query efforts, plans to meet FDA, etc.

User Image romulusaugustulus Posted - 7 hours ago

$SAVA I've got some homework to do this weekend on the options chain. Trying to decide which strike puts are best. Anyone pick a strike yet? I'm leaning toward the Dec 20. 10P's. I want to get about 25-30K deployed so I'd like to stick to the more liquid strikes. If I was braver I'd straight up short unhedged.

Analyst Ratings
HC Wainwright & Co. Neutral Aug 13, 24
Rodman & Renshaw Buy Aug 8, 24
HC Wainwright & Co. Neutral Jul 19, 24
Jones Trading Hold Jul 1, 24
HC Wainwright & Co. Neutral Jul 1, 24
HC Wainwright & Co. Buy May 17, 24
HC Wainwright & Co. Buy Mar 5, 24
HC Wainwright & Co. Buy Aug 8, 23
HC Wainwright & Co. Buy Jul 6, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
SCANNON PATRICK J MD PHD Director Director Jun 12 Option 0.95 1,000 950 1,000 06/12/23
BARBIER REMI President and CEO President and CEO May 24 Option 16.87 85,713 1,445,978 782,002 05/25/23
ROBERTSON SANFORD Director Director May 10 Option 17.64 9,284 163,770 856,851 05/10/23
BARBIER REMI President and CEO President and CEO Jun 06 Option 23.38 65,368 1,528,304 822,437 06/07/22
BARBIER REMI President and CEO President and CEO Apr 25 Option 8.63 49,460 426,840 376,112 04/25/22
GUSSIN ROBERT Z Director Director Mar 29 Option 21.95 7,470 163,966 12,434 03/29/22
ROBERTSON SANFORD Director Director Mar 25 Option 20.3 4,670 94,801 924,765 03/28/22